At what pace is the dengue vaccine market growing, and what is its estimated value?
The dengue vaccine market size has grown rapidly in recent years. It will grow from $0.64 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to growing travel and urbanization, increasing demand for effective vaccines, increasing prevalence of foreign travel exposure, increasing healthcare services, and rising mass vaccinations.
The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to the increasing incidence of dengue, increasing initiatives by several organizations, increasing clinical trials, and growing emphasis on multi-strain and tetravalent vaccine formulations. Major trends in the forecast period include increasing demand for preventative vaccines, advancements in vaccine technology, development of combination vaccines, rise in research and clinical trials for new vaccine candidates, and focus on improving vaccine efficacy and safety profiles.
Get Your Free Sample of The Global Dengue Vaccine Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp
What are the top drivers to the rising demand in the dengue vaccine market?
The rising number of dengue fever cases is expected to propel the growth of the dengue vaccine markets going forward. Dengue fever is a viral infection spread by Aedes aegypti mosquitoes, causing high fever, headaches, joint pain, and rashes. The rise in dengue fever cases is due to climate change, urbanization, inadequate mosquito control, and viral evolution. The dengue vaccine works by activating the immune system to identify and combat the dengue virus. It lessens infection severity and reduces the risk of severe complications, helping to decrease cases and hospitalizations. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, from 4.6 million cases reported in 2023. Therefore, the rising number of dengue fever cases is driving the growth of the dengue vaccine market.
How is the dengue vaccine market segmented?
The dengue vaccinemarket covered in this report is segmented –
1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users
Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report
Who are the top competitors in the dengue vaccine market?
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.
What significant trends should we anticipate in the dengue vaccine market over the forecast period?
Major companies operating in the dengue vaccine market are focused on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, to enhance protection against all four dengue virus serotypes in a single formulation. The dengue tetravalent vaccine provides immunity against all four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, received European Commission (EC) approval for QDENGA vaccine use in individuals from 4 years of age and older. It is a live-attenuated vaccine used in several dengue-endemic countries to protect against dengue fever. It uses a weakened dengue serotype two viruses as a genetic foundation for the other three serotypes. It is administered in two doses of 0.5 mL each at 0 and 3 months and targets individuals aged four years and older. A Phase 3 trial showed Qdenga has an efficacy of about 80.2% against dengue, with better results in preventing hospitalizations. Its protection lasts approximately 4.5 years, longer than many other vaccines.
Which regional trends are influencing the dengue vaccine market, and which area dominates the industry?
Asia-Pacific was the largest region in the dengue vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Dengue Vaccine Market Report 2025 Offer?
The dengue vaccine market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A dengue vaccine is a biological preparation designed to prevent dengue fever, a mosquito-borne viral disease caused by the dengue virus (DENV). If exposed in the future, dengue vaccines stimulate the body’s immune system to recognize and fight off the dengue virus.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19026
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
